GLP-1 Constipation: Evidence, Duration and Warning Signs

Evidence review

GLP-1 constipation research

How common is constipation with GLP-1 medicines?

Constipation occurs frequently enough with several GLP-1 and related incretin medicines to appear prominently in official safety information. EMA's current Wegovy product information lists constipation among the very common adverse effects of semaglutide.

In the cited semaglutide Phase 3a clinical program, constipation occurred in 24.2% of treated participants compared with 11.1% receiving placebo. For tirzepatide, current FDA Zepbound labeling reports constipation in 17% at 5 mg, 14% at 10 mg and 11% at 15 mg, compared with 5% with placebo. These dose-group percentages should not be interpreted as proof that a higher dose necessarily lowers constipation risk for an individual.

Why is constipation different from other common GLP-1 gastrointestinal effects?

One of the clearest differences is duration. Within the same cited Wegovy Phase 3a evidence pool, median reported duration was approximately 2 days for vomiting, 3 days for diarrhea, 8 days for nausea and 47 days for constipation.

This means constipation was not the most frequently reported of the four effects, but it was the most persistent by a wide margin in that particular semaglutide dataset. A useful safety profile therefore needs at least two dimensions: frequency, meaning how often the event was reported, and persistence, meaning how long reported episodes lasted.

How long can GLP-1 constipation last?

There is no universal class-wide duration. The strongest current duration figure for this page comes from Wegovy. In the cited semaglutide Phase 3a pool, constipation had a median duration of 47 days.

That does not support the statement that “GLP-1 constipation lasts 47 days.” The accurate proposition is narrower: among affected participants in the cited semaglutide Phase 3a population, the reported median duration was 47 days. A median is a population statistic rather than an expected duration for one individual.

The estimate also should not automatically be transferred to tirzepatide, liraglutide, oral semaglutide or another incretin medicine without corresponding evidence.

Can Wegovy constipation evidence be applied to Mounjaro or Zepbound?

Not directly. Semaglutide and tirzepatide are different active substances, and their safety evidence comes from separate clinical-development programs. Zepbound trial evidence confirms that constipation occurred more often in tirzepatide groups than placebo, but the Wegovy 47-day median does not establish how long constipation lasts in people receiving tirzepatide.

Why might constipation appear alongside GLP-1 treatment?

The clinical association is well established in regulatory labeling. Mechanism should be described more cautiously. GLP-1 and related incretin medicines influence gastrointestinal physiology, but an individual episode of constipation cannot be attributed to one mechanism solely from population-level trial evidence.

A useful distinction is between regulatory observation, where constipation was reported in defined treatment groups, physiological interpretation, where incretin signaling can affect gastrointestinal function, and individual diagnosis, which cannot be determined from a trial table alone.

Is constipation the opposite of diarrhea?

They are different symptom patterns, but treating them simply as opposites misses the evidence. In the cited Wegovy Phase 3a pool, diarrhea occurred in 29.7% of semaglutide-treated participants and had a median duration of three days, while constipation occurred in 24.2% and had a median duration of 47 days.

This illustrates why symptom frequency alone cannot describe the patient-experience profile found in a trial. Read the dedicated GLP-1 diarrhea page.

When does constipation become a different safety question?

Constipation by itself is a recognized gastrointestinal adverse reaction. Certain accompanying symptoms can change the clinical context. Current EMA Wegovy patient information lists bowel obstruction as a side effect whose frequency cannot be estimated from available data and describes it as a severe form of constipation that may be accompanied by symptoms such as stomach pain, bloating and vomiting.

The distinction is important: common constipation does not itself establish bowel obstruction. Severe constipation accompanied by substantial abdominal symptoms or vomiting is a different clinical question and warrants professional assessment rather than self-diagnosis from an online symptom list.

Do gastrointestinal side effects always resolve quickly?

No. The available evidence does not support that generalization. Constipation is a particularly clear example because the cited Wegovy Phase 3a pool reported a median duration much longer than for nausea, vomiting or diarrhea.

Statements such as “GLP-1 gastrointestinal side effects are temporary” therefore require qualification. Different symptoms, medicines and populations have different observed patterns.

Does oral semaglutide also have constipation in its safety profile?

Gastrointestinal effects remain relevant as GLP-1 formulations expand. Current regulatory information for oral semaglutide used in weight management includes constipation among commonly reported gastrointestinal effects. This reinforces a broader evidence rule for GLP1Scientist: formulation should be recorded explicitly whenever safety data are discussed.

Injectable and oral semaglutide share an active ingredient, but specific adverse-event percentages should remain tied to the formulation and clinical program that generated them.

What can constipation trial data tell an individual?

Clinical-trial data can establish that constipation was recognized in treated populations, that it occurred more frequently than placebo in particular trials, and that persistence may differ substantially from other gastrointestinal reactions. They cannot determine from the percentages alone whether one person will develop constipation, exactly how long it will persist, its cause in that person, whether another condition is present or whether treatment should change.

This boundary between population evidence and individual medical assessment is central to responsible interpretation.

Constipation evidence: frequency versus persistence

Wegovy / semaglutide: constipation was reported at a substantial frequency, and the cited trial program provides a comparatively long median-duration estimate.

Zepbound / tirzepatide: constipation occurred more often than placebo, but the semaglutide 47-day duration estimate should not be imported into tirzepatide evidence.

GLP-1 class context: constipation is a recognized gastrointestinal adverse effect, but one universal numerical rate or duration is not established.

Evidence limitations

Cross-trial comparisons are indirect. Wegovy and Zepbound studies differ in medicine, population, dose and other design features. Dose-group patterns do not automatically establish a simple causal dose-response relationship. Trial reporting is population-level, so it does not predict an individual's duration. Formulation also matters, and safety information can evolve as regulators update product information.

For these reasons, GLP1Scientist should preserve the exact medicine, formulation, population and source whenever a numerical adverse-event claim is presented.

Sources and references

• EMA: Wegovy product information
• EMA: Wegovy EPAR
• FDA: Zepbound prescribing information

Source access: 25 September 2026. Time-sensitive safety and product-information claims should be rechecked before later material updates.

See also the research methodology, editorial policy, corrections policy and medical disclaimer.